Javier Cortés, MD, PhD, and Julia Rotow, MD, discuss NSCLC in this CME activity titled "Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer." For the full presentation, please visit us at www.peervoice.com/TXH870.
Case Study Challenge: Managing FLT3-ITD–Positive AMLPeerVoice
Michael Heuser, MD, discusses AML in this IME activity titled "Case Study Challenge: Managing FLT3-ITD–Positive AML." For the full presentation, please visit us at www.peervoice.com/APW870.
The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...PeerVoice
Jonathan W. Riess, MD, MS, Mary Beth Beasley, MD, and Gerard A. Silvestri, MD, MS, Master FCCP, discuss NSCLC in this CME activity titled "The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC." For the full presentation, please visit us at www.peervoice.com/QHY870.
Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...PeerVoice
Xavier Montalban, MD, PhD, and Jiwon Oh, MD, PhD, FRCPC, discuss multiple sclerosis in this CE activity titled "Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?" For the full presentation, please visit us at www.peervoice.com/BBT870.
Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...PeerVoice
Lindsey Roeker, MD discusses chronic lymphocytic leukaemia in this CME activity titled "Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents." For the full presentation, please visit us at www.peervoice.com/HZH870.
A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...PeerVoice
Sara Hurvitz, MD, Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD, discuss breast cancer in this CME activity titled "A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer." For the full presentation, please visit us at www.peervoice.com/UGT870.
Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...PeerVoice
Christian Récher, MD, PhD, Pau Montesinos, MD, PhD, and Christian Thiede, MD, discuss acute myeloid leukaemia in this IME activity titled "Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics." For the full presentation, please visit us at www.peervoice.com/GYE870.
Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...PeerVoice
Maria Craig, MBBS, PhD, FRACP, MMed(ClinEpid) and Timothy Barrett, MB, BS, PhD discuss type 2 diabetes in children and adolescents in this CE activity titled "Treating T2D in People of Younger Age in This Day and Age: How Would You Manage These Children and Adolescents With T2D?" For the full presentation, please visit us at www.peervoice.com/GBR870.
Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...PeerVoice
Thomas Powles, MBBS, MRCP, MD, discusses urothelial carcinoma in this CE activity titled "Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy." For the full presentation, please visit us at www.peervoice.com/NYE870.
Case Study Challenge: Managing FLT3-ITD–Positive AMLPeerVoice
Michael Heuser, MD, discusses AML in this IME activity titled "Case Study Challenge: Managing FLT3-ITD–Positive AML." For the full presentation, please visit us at www.peervoice.com/APW870.
The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...PeerVoice
Jonathan W. Riess, MD, MS, Mary Beth Beasley, MD, and Gerard A. Silvestri, MD, MS, Master FCCP, discuss NSCLC in this CME activity titled "The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC." For the full presentation, please visit us at www.peervoice.com/QHY870.
Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...PeerVoice
Xavier Montalban, MD, PhD, and Jiwon Oh, MD, PhD, FRCPC, discuss multiple sclerosis in this CE activity titled "Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?" For the full presentation, please visit us at www.peervoice.com/BBT870.
Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...PeerVoice
Lindsey Roeker, MD discusses chronic lymphocytic leukaemia in this CME activity titled "Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents." For the full presentation, please visit us at www.peervoice.com/HZH870.
A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...PeerVoice
Sara Hurvitz, MD, Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD, discuss breast cancer in this CME activity titled "A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer." For the full presentation, please visit us at www.peervoice.com/UGT870.
Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...PeerVoice
Christian Récher, MD, PhD, Pau Montesinos, MD, PhD, and Christian Thiede, MD, discuss acute myeloid leukaemia in this IME activity titled "Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics." For the full presentation, please visit us at www.peervoice.com/GYE870.
Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...PeerVoice
Maria Craig, MBBS, PhD, FRACP, MMed(ClinEpid) and Timothy Barrett, MB, BS, PhD discuss type 2 diabetes in children and adolescents in this CE activity titled "Treating T2D in People of Younger Age in This Day and Age: How Would You Manage These Children and Adolescents With T2D?" For the full presentation, please visit us at www.peervoice.com/GBR870.
Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...PeerVoice
Thomas Powles, MBBS, MRCP, MD, discusses urothelial carcinoma in this CE activity titled "Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy." For the full presentation, please visit us at www.peervoice.com/NYE870.
The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal HaemoglobinuriaPeerVoice
Jeffrey Szer, MBBS, FRACP, discusses PNH in this IME activity titled "The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria." For the full presentation, please visit us at www.peervoice.com/ZHK870.
When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...PeerVoice
Asma Khalil, MBBCh, MD(Res), FRCOG, MSc(Epi), and Enrico Lopriore, MD, PhD, discuss haemolytic disease of the fetus and newborn in this CE activity titled "When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease of the Fetus and Newborn." For the full presentation, please visit us at www.peervoice.com/BKD870.
CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...PeerVoice
Fatos Pinar Topsever, MD and Jennifer Green, MD discuss CKD in T2DM in this CME activity titled "CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes." For the full presentation, please visit us at www.peervoice.com/QKR870.
Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...PeerVoice
Lisa Licitra, MD, and Barbara Burtness, MD, discuss head and neck cancer in this CE activity titled "Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?" For the full presentation, please visit us at www.peervoice.com/YZV870.
Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...PeerVoice
Dirk Arnold, MD, Chiara Cremolini, MD, PhD, and Nicola Normanno, MD, discuss metastatic colorectal cancer in this CE activity titled "Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer." For the full presentation, please visit us at www.peervoice.com/RAS870.
Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...PeerVoice
Ali Aamer Habib, MD, and Martijn Tannemaat, MD, PhD, discuss generalised myasthenia gravis in this CE activity titled "Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies for Generalised Myasthenia Gravis." For the full presentation, please visit us at www.peervoice.com/JEG870.
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a ...PeerVoice
Jonathan W. Goldman, MD, Xiuning Le, MD, PhD, and Diana N. Ionescu, MD, discuss NSCLC in this IME activity titled "Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC." For the full presentation, please visit us at www.peervoice.com/HPP870.
Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...PeerVoice
Javed Butler, MD, MPH, MBA, Michael Böhm, MD, Alexandre Mebazaa, MD, PhD, and Antoni Bayés-Genís, MD, PhD, FESC, FHFA, discuss heart failure in this CE activity titled "Practical Perspectives and Straightforward Strategies for Optimising GDMT in HFrEF: The Role of ARNI as a Fundamental Building Block." For the full presentation, please visit us at www.peervoice.com/QJJ870.
MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...PeerVoice
Bertrand Tombal, MD, PhD, Edmund Chiong, MBBS, PhD, FRCS / FAMS, and Louise Emmett, MBChB, MD, discuss prostate cancer in this IME activity titled "MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes." For the full presentation, please visit us at www.peervoice.com/EUM870.
Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...PeerVoice
Wisia Wedzicha, MD, FRCP and Alberto Papi, MD discuss chronic obstructive pulmonary disease in this [CME] activity titled "Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care." For the full presentation, please visit us at www.peervoice.com/ZFW870.
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...PeerVoice
Nils Erik Gilhus, MD, PhD, and Sarah Hoffmann, MD, PhD, MSc, discuss generalised myasthenia gravis in this CE activity titled "Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis." For the full presentation, please visit us at www.peervoice.com/PBV870.
The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...PeerVoice
Marwan Fakih, MD, discusses colorectal cancer in this CME activity titled "The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line." For the full presentation, please visit us at www.peervoice.com/SSC870.
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRCPeerVoice
Marwan Fakih, MD, Tanios Bekaii-Saab, MD, and Dustin Deming, MD, discuss colorectal cancer in this CME activity titled "Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC." For the full presentation, please visit us at www.peervoice.com/AQR870.
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...PeerVoice
David M. G. Halpin, MB BS, DPhil, FERS discusses chronic obstructive pulmonary disease in this CME activity titled "The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death." For the full presentation, please visit us at www.peervoice.com/UWS870.
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...PeerVoice
Ana C. Garrido-Castro, MD and Sarah L. Sammons, MD discuss breast cancer in this CME activity titled "TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct." For the full presentation, please visit us at www.peervoice.com/JJH870.
Building a Better Approach to Obesity Care in Our Clinical PracticesPeerVoice
Carel le Roux, MD, PhD, discusses obesity in this CME activity titled "Building a Better Approach to Obesity Care in Our Clinical Practices." For the full presentation, please visit us at www.peervoice.com/HPE870.
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...PeerVoice
Laurent Servais, MD, PhD and Giovanni Baranello, MD, PhD discuss the clinical presentation of hypotonia in this IME activity titled "Catch Them Before They Fall: A Call to Action for Comprehensive Testing for Hypotonia in Paediatric Patients." For the full presentation, please visit us at www.peervoice.com/SNX870.
Radioligand Therapy and Therapeutic Sequencing in mCRPCPeerVoice
Elena Castro, MD, PhD, discusses prostate cancer in this IME activity titled "Radioligand Therapy and Therapeutic Sequencing in mCRPC." For the full presentation, please visit us at www.peervoice.com/AKT870.
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...PeerVoice
Philip James Tozer, MBBS, MD(Res), FRCS, Krisztina Barbara Gecse, MD, PhD, and Jordi Rimola, MD, PhD, discuss complex perianal fistula in this CME activity titled "Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring the Who, When, and How for Stem Cell Therapy." For the full presentation, please visit us at www.peervoice.com/GWC870.
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...PeerVoice
Claus Vogelmeier, MD, and Nicola Hanania, MD, MS, discuss chronic obstructive pulmonary disease in this CE activity titled "Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD." For the full presentation, please visit us at www.peervoice.com/JHP870.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal HaemoglobinuriaPeerVoice
Jeffrey Szer, MBBS, FRACP, discusses PNH in this IME activity titled "The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria." For the full presentation, please visit us at www.peervoice.com/ZHK870.
When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...PeerVoice
Asma Khalil, MBBCh, MD(Res), FRCOG, MSc(Epi), and Enrico Lopriore, MD, PhD, discuss haemolytic disease of the fetus and newborn in this CE activity titled "When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease of the Fetus and Newborn." For the full presentation, please visit us at www.peervoice.com/BKD870.
CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...PeerVoice
Fatos Pinar Topsever, MD and Jennifer Green, MD discuss CKD in T2DM in this CME activity titled "CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes." For the full presentation, please visit us at www.peervoice.com/QKR870.
Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...PeerVoice
Lisa Licitra, MD, and Barbara Burtness, MD, discuss head and neck cancer in this CE activity titled "Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?" For the full presentation, please visit us at www.peervoice.com/YZV870.
Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...PeerVoice
Dirk Arnold, MD, Chiara Cremolini, MD, PhD, and Nicola Normanno, MD, discuss metastatic colorectal cancer in this CE activity titled "Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer." For the full presentation, please visit us at www.peervoice.com/RAS870.
Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...PeerVoice
Ali Aamer Habib, MD, and Martijn Tannemaat, MD, PhD, discuss generalised myasthenia gravis in this CE activity titled "Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies for Generalised Myasthenia Gravis." For the full presentation, please visit us at www.peervoice.com/JEG870.
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a ...PeerVoice
Jonathan W. Goldman, MD, Xiuning Le, MD, PhD, and Diana N. Ionescu, MD, discuss NSCLC in this IME activity titled "Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC." For the full presentation, please visit us at www.peervoice.com/HPP870.
Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...PeerVoice
Javed Butler, MD, MPH, MBA, Michael Böhm, MD, Alexandre Mebazaa, MD, PhD, and Antoni Bayés-Genís, MD, PhD, FESC, FHFA, discuss heart failure in this CE activity titled "Practical Perspectives and Straightforward Strategies for Optimising GDMT in HFrEF: The Role of ARNI as a Fundamental Building Block." For the full presentation, please visit us at www.peervoice.com/QJJ870.
MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...PeerVoice
Bertrand Tombal, MD, PhD, Edmund Chiong, MBBS, PhD, FRCS / FAMS, and Louise Emmett, MBChB, MD, discuss prostate cancer in this IME activity titled "MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes." For the full presentation, please visit us at www.peervoice.com/EUM870.
Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...PeerVoice
Wisia Wedzicha, MD, FRCP and Alberto Papi, MD discuss chronic obstructive pulmonary disease in this [CME] activity titled "Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care." For the full presentation, please visit us at www.peervoice.com/ZFW870.
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...PeerVoice
Nils Erik Gilhus, MD, PhD, and Sarah Hoffmann, MD, PhD, MSc, discuss generalised myasthenia gravis in this CE activity titled "Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis." For the full presentation, please visit us at www.peervoice.com/PBV870.
The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...PeerVoice
Marwan Fakih, MD, discusses colorectal cancer in this CME activity titled "The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line." For the full presentation, please visit us at www.peervoice.com/SSC870.
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRCPeerVoice
Marwan Fakih, MD, Tanios Bekaii-Saab, MD, and Dustin Deming, MD, discuss colorectal cancer in this CME activity titled "Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC." For the full presentation, please visit us at www.peervoice.com/AQR870.
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...PeerVoice
David M. G. Halpin, MB BS, DPhil, FERS discusses chronic obstructive pulmonary disease in this CME activity titled "The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death." For the full presentation, please visit us at www.peervoice.com/UWS870.
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...PeerVoice
Ana C. Garrido-Castro, MD and Sarah L. Sammons, MD discuss breast cancer in this CME activity titled "TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct." For the full presentation, please visit us at www.peervoice.com/JJH870.
Building a Better Approach to Obesity Care in Our Clinical PracticesPeerVoice
Carel le Roux, MD, PhD, discusses obesity in this CME activity titled "Building a Better Approach to Obesity Care in Our Clinical Practices." For the full presentation, please visit us at www.peervoice.com/HPE870.
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...PeerVoice
Laurent Servais, MD, PhD and Giovanni Baranello, MD, PhD discuss the clinical presentation of hypotonia in this IME activity titled "Catch Them Before They Fall: A Call to Action for Comprehensive Testing for Hypotonia in Paediatric Patients." For the full presentation, please visit us at www.peervoice.com/SNX870.
Radioligand Therapy and Therapeutic Sequencing in mCRPCPeerVoice
Elena Castro, MD, PhD, discusses prostate cancer in this IME activity titled "Radioligand Therapy and Therapeutic Sequencing in mCRPC." For the full presentation, please visit us at www.peervoice.com/AKT870.
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...PeerVoice
Philip James Tozer, MBBS, MD(Res), FRCS, Krisztina Barbara Gecse, MD, PhD, and Jordi Rimola, MD, PhD, discuss complex perianal fistula in this CME activity titled "Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring the Who, When, and How for Stem Cell Therapy." For the full presentation, please visit us at www.peervoice.com/GWC870.
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...PeerVoice
Claus Vogelmeier, MD, and Nicola Hanania, MD, MS, discuss chronic obstructive pulmonary disease in this CE activity titled "Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD." For the full presentation, please visit us at www.peervoice.com/JHP870.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system